← Back to Patent Explorer
US4255329A Expired / Lapsed US ⏱️ 0.0 years remaining

Double receptor fluorescent immunoassay

Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1979-04-02
•
Granted: 1981-03-10
•
Expires: 1999-04-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A novel sensitive method for determining qualitatively and quantitatively the presence of a wide variety of physiologically active organic compounds (ligand) and their receptors is provided. The method employs a reagent which involves bonding a compound having structural similarity to the compound to be determined (ligand analog) to a fluorescing compound. The unknown compound is referred to as a ligand, the conjugate of the structurally similar compound and fluorescer is referred to as ligand analog-fluorescer, and compounds which recognize a specific structure and bind to such structure as referred to as receptors and are normally antibodies. The fluorescer which is chosen will have either a change is quantum yield or a change in its emission and/or absorption spectra or all of them, when bound to antibody, as compared to being unbound. For the purposes of the assay, all that is required is that there be a change in the emission intensity at some wavelength or band of wavelengths. The rate at which fluorescer antibody binds to the fluorescer portion of the ligand analog-fluorescer or the amount of fluorescer antibody bound to the fluorescer portion of the ligand analog-fluorescer at equilibrium will be related to the amount of ligand antibody bound to the ligand analog portion of the ligand analog-fluorescer. Therefore, by combining antibodies to both ligand and fluorescer, with ligand analog-fluorescer and an unknown, one can determine the amount of ligand present in the unknown by relating the emission intensity at a particular wavelength or band of wavelengths to standards. Alternatively, by combining an unknown containing antiligand with fluorescer antibody and ligand analog-fluorescer, one can determine the amount of receptor in the unknown.

Inventors

  • 👤 Edwin F. Ullman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 14:50
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/536; G01N33/542; Y; Y10; Y10S; Y10S436/00; Y10S436/80; Y10S436/815; Y10S436/816; Y10S436/817

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 17 words
A compound of the formula: ##STR3## wherein the amino group is at the 4 or 5 position.
Claim 2
Dependent Claim 17 words
A compound of the formula: ##STR3## wherein the amino group is at the 4 or 5 position.
Claim 3
Dependent Claim 85 words
A compound of the formula: Hap-X-Fl wherein Fl is a fluorescer selected from the group consisting of fluoresceins, rosamines and rhodamines having an absorption maximum above about 350nm; X is a linking group of from 2 to 8 atoms other than hydrogen, which are carbon, nitrogen, oxygen and sulfur and having a non-oxo-carbonyl functionality forming an ester or amide; and Hap is an haptenic drug selected from the group consisting of morphine, triiodothyronine of from 3 to 4 iodo groups, diphenylhydantoin, phenobarbital, dibenzazepine and 3-ketodigoxigenin.
Claim 4
Dependent Claim 85 words
A compound of the formula: Hap-X-Fl wherein Fl is a fluorescer selected from the group consisting of fluoresceins, rosamines and rhodamines having an absorption maximum above about 350nm; X is a linking group of from 2 to 8 atoms other than hydrogen, which are carbon, nitrogen, oxygen and sulfur and having a non-oxo-carbonyl functionality forming an ester or amide; and Hap is an haptenic drug selected from the group consisting of morphine, triiodothyronine of from 3 to 4 iodo groups, diphenylhydantoin, phenobarbital, dibenzazepine and 3-ketodigoxigenin.
Claim 5
Dependent Claim 35 words
A compound according to claim 2, wherein Hap is polyiodothyronine and is of the formula ##STR4## wherein: a is 0 or 1; and R is hydrogen or alkoxyl of from 1 to 3 carbon atoms.
Claim 6
Dependent Claim 13 words
A compound according to claim 2, wherein Hap is of the formula ##STR5##
Claim 7
Dependent Claim 13 words
A compound according to claim 2 wherein Hap is of the formula ##STR6##
Claim 8
Dependent Claim 13 words
A compound according to claim 3, wherein Hap is of the formula ##STR7##
Claim 9
Dependent Claim 32 words
A compound according to claim 2, wherein Hap is of the formula ##STR8## wherein: A is hydrogen or a bond being taken together with the other bond to define a double bond.

References Cited (Backward Citations)

US3817837A Cited
US3855208A Cited
US3981982A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-03-09 1984-09-08 1985-03-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-03-09 1988-09-08 1989-03-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-03-09 1992-09-08 1993-03-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag